Caribou Biosciences said it is reviewing strategic alternatives while cutting resources and halting its two clinical-phase allogeneic CAR-T programs. The company also announced additional cost-reduction steps amid what CEO Rachel Haurwitz described as an inability to secure sufficient capital for responsible development in today’s financing environment for off-the-shelf CAR-T therapies. The move underscores how funding scarcity can translate quickly into pipeline stoppages for companies positioned in technically ambitious, capital-intensive modalities. Caribou’s plans include reducing its workforce (97 people as of its Feb. 27, 2024 10-K) and pausing progress on its lead programs while it evaluates next steps.